Welcome to our dedicated page for The Oncology Institute news (Ticker: TOIIW), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (Nasdaq: TOI for common stock and TOIIW for redeemable warrants) regularly issues news that reflects its role in value-based community oncology care. Company press releases highlight its efforts to advance specialized, evidence-based cancer treatment in community settings, supported by a multi-state network of clinics and affiliate locations.
News coverage often focuses on operational performance and financial updates, including quarterly financial results, guidance revisions, and discussions of revenue mix across segments such as patient services, dispensary activities, and capitation arrangements. These updates provide context on how the organization’s value-based oncology model translates into reported revenue, gross profit, and non-GAAP measures such as Adjusted EBITDA and Free Cash Flow.
Readers can also expect announcements about clinical and quality milestones. The Oncology Institute has reported results from participation in federal oncology payment models, including Medicare savings and quality scores in the Enhancing Oncology Model, and has described programs like its High Value Cancer Care initiative and 24/7 symptom management support. Other news items cover the launch of disease-focused centers, such as a Lung Cancer Center of Excellence in Florida, and the expansion of pharmacy and dispensary operations.
Corporate governance and leadership developments are another recurring theme. Recent releases have detailed board changes, including director resignations and appointments, as well as promotions within the executive team in areas such as information technology and people operations. The company also issues news about partnerships, for example its collaboration with Ascertain to deploy AI-powered automation for administrative workflows.
Investors and observers who follow TOI and TOIIW can use this news stream to monitor financial guidance, operational initiatives, technology partnerships, and clinical program developments that the company chooses to highlight in its public communications.
The Oncology Institute of Hope and Innovation (TOI) has expanded its presence in Southern California by opening a new clinic in Culver City on March 7, 2022, and enhancing its Riverside location on March 14, 2022. These expansions aim to improve access to quality oncology care. The Culver City clinic provides comprehensive medical services while the Riverside clinic tripled its infusion space to accommodate a growing patient population. TOI's commitment to advancing cancer care includes a strong emphasis on clinical trials and outpatient services, benefiting both patients and clinicians.
The Oncology Institute (NASDAQ: TOI) reported record revenue of $203 million for 2021, reflecting an 8.3% increase year-over-year.
For Q4, revenue reached $52 million, a 6.8% increase, despite a net loss of $10 million and significant SG&A expenses of $48 million due to growth investments.
Looking ahead to 2022, TOI anticipates revenue of $270 million to $310 million and projects managing between 1.75 million to 2.0 million lives under value-based contracts.
CERRITOS, Calif., March 8, 2022 – The Oncology Institute of Hope and Innovation (NASDAQ: TOI) announced that CEO Brad Hively will participate in the Jefferies Value-Based Healthcare Summit in Miami on March 14 at 1:40 pm EST. Hively has over 20 years of healthcare experience, transforming TOI into a leading oncology provider with over 50 clinics nationwide. The institute offers innovative, value-based cancer care to approximately 1.6 million patients. Investors can access a webcast of the event on the company’s website.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has announced the promotions of Dr. Daniel Virnich to President and Dr. Matt Miller to Chief Operating Officer, effective March 15, 2022. These changes are part of a response to TOI's rapid growth. Dr. Virnich, who joined in 2020, will oversee various functions including Operations and Compliance, while Dr. Miller will manage all field and central operations nationally. Both leaders have previously driven tangible improvements in operational efficiency and patient satisfaction, positioning TOI for continued development in specialized oncology care.
The Oncology Institute (TOI) has established a value-based agreement with MaxHealth to deliver medical oncology care in Pinellas and Hillsborough Counties, beginning March 1, 2022. This partnership aims to enhance patient care through TOI's innovative oncology model, which includes over 170 clinical trials and comprehensive oncology services. The initiative targets expansion into neighboring counties, reflecting TOI's commitment to improving cancer care accessibility. Both organizations emphasize a shared goal of personalized patient care and satisfaction.
The Oncology Institute of Hope and Innovation (TOI) has entered a value-based agreement with MaxHealth to provide medical oncology care in Pinellas and Hillsborough Counties, Florida. This partnership, effective from March 1, 2022, aims to enhance cancer care access and quality through community-focused services, including clinical trials and stem cell transplants. TOI plans to expand this initiative to neighboring counties shortly. Both organizations emphasize a commitment to personalized care and improving patient satisfaction.
The Oncology Institute (TOI) will release its fourth quarter and full year results on March 10, 2022, after market close. Following the results, a conference call is scheduled for 5:00 p.m. ET, accessible via phone or webcast. TOI specializes in delivering advanced, value-based cancer care to over 1.5 million patients, with 54 clinic locations and a team of 80+ clinicians. Their services include clinical trials, stem cell transplants, and transfusions. Interested parties can join the call and access a replay through the provided contact information.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has expanded its footprint by opening its 54th clinic in Lakeland, Florida, enhancing oncology services available in Polk County. This new clinic, which is the sixth in Florida, aims to provide patients with convenient access to oral chemotherapeutics and blood transfusion services. With experienced providers onboard, the institute continues to showcase its commitment to value-based cancer care. The expansion aligns with TOI's efforts to elevate healthcare standards and meet growing patient needs in the region.
Summary not available.
TOI has expanded its physician network by acquiring the practices of Dr. Ellsworth R. Grant and Dr. Leo E. Orr, adding to its team of over 80 clinicians. This acquisition will enhance TOI's ability to provide value-based oncology care to more than 1.5 million patients across its locations.
The new facility in Westlake offers advanced medical services similar to other TOI clinics, enhancing patient access to high-quality cancer care.